EIP
European Immunogenicity Platform

17th OPEN SCIENTIFIC EIP SYMPOSIUM ON IMMUNOGENICITY OF BIOPHARMACEUTICALS

Program

March 16th – 19th 2026

Monday, March 16th 2026

Trainings

09:00 **Welcome and Introduction by the EIP Chairman**
Daniel Kramer, Sanofi

Trainings – Parallel Sessions

09:15	**Immunogenicity Beginner Training – Topic to be Announced** EIP Team	**Immunogenicity Advanced Training – Topic to be Announced** EIP Team
10:15	**Coffee Break**	
10:45	**Bring Your Own Problems – Break Out Session 1** EIP Team	**Bring Your Own Problems – Break Out Session 2** EIP Team
12:15	**Lunch Break**	

Main Program

13:45 **Keynote Presentation: Innate Immunity**
Bruno Lemaître, EPFL

Session 1: Immunogenicity of New Modalities
Session Chair: Lydia Michaut, Novartis

14:45 **Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASOs, siRNAs, and non-vaccine mRNA/LNPs**
Joanna Grudzinska-Goebel, Bayer

15:15 **Imlifidase Treatment for Overcoming Pre-Formed Immunity**
Hitto Kaufmann, Hansa Biopharma

15:45 **Minimizing immunogenicity testing for development of oligonucleotide therapeutics: A risk-based strategy**
An Zhao, Regeneron Pharmaceuticals

16:15 **Coffee Break**

16:45 **Transient blockade of the CD28/B7 costimulatory pathway with abatacept inhibits immune responses to AAV vector and transgene product**
Rebecca Xicluna, Roche

17:15 **Advancing Immunogenicity Testing: Overcoming Drug Tolerance in a Neutralising Antibody Assay for an mRNA-Based Oncology Therapeutic**
Juliane Ober-Blobaum, Moderna

17:45 **Immunogenicity Risk Assessment and Mitigation Strategy for AAV Gene Therapy**
Hélène Haegel, Roche

18:15 **End of Day 1**

Tuesday, March 17th 2026

Session 2: Regulatory

Chair: Daniel Kramer, Sanofi

9:00	**New Version of the FDA Immunogenicity Guidance (title to be confirmed)** Joao Pedras-Vasconcelos, FDA
9:30	**Future Direction of Immunogenicity at FDA (title to be confirmed)** Susan Kirshner, FDA
10:00	**Harmonizing Adalimumab Anti-drug Antibody Assays through WHO International Standards** Meenu Wadhwa, Medicines and Healthcare Products Regulatory Agency
10:30	**Coffee Break**

Session 3: Immunogenicity of Therapeutic Peptides

Chair: Arno Kromminga, BioNTech

11:00	**Immunogenicity Risk in Peptide Therapeutics: Navigating Complexity, Prediction tools, and Bioanalytical Strategies** Montserrat Puig, Merck Sharp & Dohme
11:30	**Clinical Pharmacology Perspectives on Immunogenicity of Peptide Drugs** Rajabi Mohsen, Novartis
12:00	**Aligning Regulatory Expectations on Immunogenicity to Support Peptide Drug Product Approvals** Laura Salazar-Fontana, Immunogenicity Integrated
12:30	**Lunch Break**

Session 4: Immunogenicity Assays

Chair: Christopher Tiedje, BioAgilytix

14:00	**EIP Immunogenicity Assays and EIP Immunogenicity Risk Assessment Working Group Update** Linlin Luo, Merck Sharp & Dohme on behalf of EIP Assay Working Group Veerle Snoeck, UCB & Joanna Grudzinska-Goebel, Bayer on behalf of the EIP Immunogenicity Risk Assessment (IRA) Working Group
14:30	**Overcoming Unexpected Interference in a Highly Drug-Tolerant and Ultrasensitive ADA-SPEAD Assay** Florian Anlauff, BioAgilytix
14:45	**PABAD in Practice: Achieving High Drug Tolerance in NAb Assays** Lysie Champion, Celerion
15:15	**When Generic Assays Succeed (and Fail): Case Studies and a Fit-for-Purpose Strategy for Non-Clinical ADA Support** Noor Bodrul, Roche
15:45	**Coffee Break**

16:15	**The Immunogenicity Nexus: Investigating the Predictive Relationship Between Early-Onset ADA Kinetics in NHP and Human Immune Responses** Yana Vandenbossche, Sanofi
16:45	**Positive Controls in Immunogenicity Assays: Case Studies and Best Practices** Esther Biemans, Ardena
17:15	**A Drug and Target-Tolerant Hybrid LBA-LC-MS Method for (Semi-)Quantification of ADA Isotopes, Using a Single-Tier Approach** Hendrik Folkerts, ICON Bioanalytical Laboratory
17:45	**End of Day 2**

Wednesday, March 18th 2026

Session 5: Biosimilars

Chair: Denise Sickert

09:00 **EIP Biosimilar Working Group Update**
Martin Ullmann, Fresenius Kabi on behalf of EIP

09:15 **Establishing In-Vitro Assays for Non-Clinical Immunogenicity Assessment of Biosimilars**
Marc Rosenbaum, Hexal AG

09:45 **Biosimilar Medicines: The Story of European Pioneering Success in Advancing Patient Access to Lifesaving Biologic Treatment**
Karsten Roth, Polpharma Biologics

10:15 **A Comparative Analysis of Antidrug Antibody Incidences of EU and US Approved Biosimilars and their Reference Products Reported in Single-Dose PK Studies in Healthy Volunteers and Multidose Studies in Patients**
Hans Ebbers, Alvotech

10:45 **Coffee Break**

Session 6: Prediction of immunogenicity

Chair: Sofie Pattyn

11:15 **EIP NCIRA Working Group Update**
Sebastian Spindeldreher, Integrated Biologix

11:30 **Immunogenicity Risk Assessment: Enabling Quality by Design in Therapeutic Protein Discovery and Development**
Tim Hickling, Quasor & Sophie Tourdot, Pfizer

12:00 **How to translate pre-clinical in silico immunogenicity profiling results to clinical immunogenicity rates?**
Michael Gutknecht, Novartis

12:30 **Poster/Exhibition Lunch**

13:30 **Unmasking Hidden Epitopes: Bridging In Silico Prediction and MAPPs Detection in Immunogenicity Assessment**
Andreas Hollenstein, Roche

14:00 **Advancing Preclinical Immunogenicity Prediction: Machine Learning on Clinical Data and Pathogen Cross-Reactivity Integration**
Olga Obrezanova, Astra Zeneca

14:30 **An Innovative Reductionist Antigen Presenting System to Rapidly Screen Protein Immunogenicity in Human Lysosomes**
Sergio Gabriele Colangelo, RBM S.p.A., an affiliate of Merck KGaA

Short Talk (10 minutes)

15:00 **Improving TCR-pMHC Structure Prediction with TCR-Specific Spatial Restraint Features**
Joakim Nøddeskov, Technical University of Denmark

15:15 **Coffee Break**

Session 7: Clinical Relevance of Immunogenicity
Chair: Noel Smith, Lonza

15:45 **Assessment of Long-term Immunogenicity of Lonapegsomatropin in Children With Growth Hormone Deficiency**
Per Holse Mygind, Ascendis

Short Talk (10 minutes)

16:15 **Immunogenicity Assessment in Acromegaly Patients Treated with Ready-to-Use, Sustained-Release, Octreotide Subcutaneous Depot**
K. Järås, Camurus

16:30 **Immunogenicity Publication Bias and Its Consequences for Predictive Models: A Call for Transparent Reporting**
Sophie Tascedda, RC2NB

16:45 **End of Day 3**

Session 8: Social Event (reconvene at 17:15 in the Altis lobby)
Chair: Barbara Vercruyssen

Thursday, March 19th 2026

Workshop – Parallel Sessions

09:00	**Deep Dive 1:** **Recent Publication "Immunogenicity Risk Assessment for Tailored Mitigation and Monitoring of Biotherapeutics and Biosimilars"** Veerle Snoeck, UCB and Joanna Grudzinska-Goebel, Bayer on behalf of the EIP Immunogenicity Risk Assessment (IRA) Working Group	**Deep Dive 2:** **Three Recent Publications of the NCIRA Working Group (EIP Recommendations for Dendritic Cell Maturation Assays, MAPPs and T-Cell Assays)** Sebastian Spindeldreher, Integrated Biologix on behalf of the EIP NCIRA Working Group
10:30	**Coffee Break**	
11:00	**In Depth Discussion Deep Dive 1** EIP Team	**In Depth Discussion Deep Dive 2** EIP Team
12:30	**Summary and Outlook of the EIP Chairman** Daniel Kramer, Sanofi	
12:45	**End of the conference**	